ProfileGDS5678 / 1455314_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 91% 92% 90% 91% 89% 92% 92% 92% 93% 91% 93% 93% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.5839692
GSM967853U87-EV human glioblastoma xenograft - Control 27.3647591
GSM967854U87-EV human glioblastoma xenograft - Control 37.6222292
GSM967855U87-EV human glioblastoma xenograft - Control 47.4265390
GSM967856U87-EV human glioblastoma xenograft - Control 57.6077191
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.810489
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.3124392
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.4891692
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.6208892
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7991593
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.422491
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9198793
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.8592893
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.7055492